Related Experiment Videos
Alternatives to mega-trials in cardiovascular disease
1Department of Cardiovascular Medicine, University Hospital, Nottingham, UK.
Cardiovascular Drugs and Therapy
|January 1, 1997
Summary
Mega-trials in cardiovascular disease research face challenges. Equivalence trials offer a promising alternative for evaluating new cardiovascular drugs when large-scale studies are impractical.
Area of Science:
- Cardiovascular Disease Research
- Clinical Trial Design
Background:
- Mega-trials involving thousands of patients are dominant in cardiovascular disease research.
- Significant challenges exist in conducting and interpreting results from large-scale clinical trials.
Purpose of the Study:
- To explore the limitations of current large-scale trial methodologies in cardiovascular disease.
- To identify and discuss alternative strategies for evaluating new cardiovascular drugs.
- To propose a viable alternative to mega-trials for drug introduction.
Main Methods:
- Discussion of limitations inherent in meta-analysis.
- Analysis of trials utilizing combined and surrogate endpoints.
- Consideration of properly organized equivalence trials.
Main Results:
- Mega-trials present practical and interpretational difficulties.
- Meta-analysis and trials with combined/surrogate endpoints have notable limitations.
- Equivalence trials demonstrate potential as a practical alternative.
Conclusions:
- Alternative strategies are necessary due to the challenges posed by mega-trials.
- Properly designed equivalence trials represent the most promising alternative to mega-trials for introducing new cardiovascular drugs.